date,title,content,company
"  January 11, 2023 / 02:21 PM IST  ",Kumar Mangalam Birla’s Hindalco to sell first bond in a decade,"Billionaire Kumar Mangalam Birla’s flagship metals company is returning to the bond market after a decade-long hiatus, looking to raise funds to meet regulatory requirements.Hindalco Industries Ltd. is looking to sell a bond for as much as 7 billion rupees ($86 million), according to an exchange filing on Wednesday. If the transaction goes ahead, it would the firm’s first bond sale since 2012, Bloomberg-compiled data show.Regulators in India require large companies to meet 25% of their annual funding requirements by issuing bonds, a policy designed to deepen the market.Hindalco’s board approved a proposal to raise as much as 10 billion rupees through bonds, loans, debentures and other securities in November. Managing Director Satish Pai said at the time that approval to raise funds through notes was to fulfill regulatory requirements.",Hindalco Industries Ltd.
"  January 11, 2023 / 03:23 PM IST  ",A portfolio of 19 stocks to stick with for a rewarding 2023,"                        The year 2022 was difficult for the Indian stock market. Nevertheless, amid volatility and uncertainty, the market did throw up several winners. While the outlook for 2023 is clouded, with forecasts ranging from extreme optimism to pessimism, we believe a well-researched portfolio can still produce gainers. Here’s a 19-stock portfolio that can help navigate an uncertain year. Wishing all our readers a very Happy New Year and a rewarding year of investing with MC Pro.

The following are the 19...
                    ",Maruti Suzuki India Ltd.
"  January 11, 2023 / 09:58 AM IST  ",Axis Bank to pick up remaining 7% stake in Max Life; Jefferies sees 16% upside in stock,"Complying with the guidelines laid out by the insurance regulator, Axis Bank on Tuesday said it has entered into a revised agreement to acquire an additional 7 percent stake in Max Life Insurance at fair market value.Earlier, Axis Entities had collectively acquired 12.99 percent of the equity share capital of Max Life. “We have entered into revised agreements with Max Financial agreeing that the valuation for the right to acquire the balance 7 percent equity stake of Max Life would be at fair market value using discounted cash flows,” the bank said in an exchange filing.Follow our live blog for all the market actionAccording to foreign brokerage firm Jefferies, the deal on fair value would imply a transaction value of Rs 1,100-2,100 crore and Axis Bank will have to pay an Rs 700-1,700 crore more. “Deal is positive for Max Life and Max Financial Services,” it noted.“Axis Bank may recover the value with higher commission that may impact the margin a bit. Max Life has lagged peers on growth in 9MFY23 and a pick-up here will aid re-rating,” it said. Max Life Insurance had 269 offices with Rs 1.07 lakh crore of assets under management as of FY22.Jefferies has a 'buy' rating on Axis Bank with a target price of Rs 1,110 per share. The stock was trading flat at Rs 949.50 apiece on the NSE in early trading hours on Wednesday. It has gained 40 percent in the past six months. Max Financial Services was also trading flat at Rs 775 apiece at the time.In 2020, Axis Bank and Max Financial Services had first announced the deal under which the lender proposed to acquire 29 percent stake in Max Life Insurance. ""Should the merger not be completed by a pre-agreed timeline, the parties have contractually agreed on certain other outcomes which are detailed in the transaction documents, including a swap of Axis Bank shareholding to Max Financial, tax consequence of which will be equally borne by the parties,"" the companies had said in a regulatory filing and also described them as 'Value Creation Options'.The transaction also provided for a ‘Put option’ under which Axis Bank could sell all its shares to Max Financial Services at Rs 294 apiece if the value creation option was not consummated. Later, sector watchdog Insurance Regulatory and Development Authority of India (IRDAI) raised concerns over some clauses in the merger agreement, including the ‘Put option’.IRDAI also slapped Rs 3 crore and Rs 2 crore fines on Max Life Insurance and Axis Bank for violation of various provisions relating to the deal. ",Max Financial Services Ltd.
"  January 11, 2023 / 12:03 PM IST  ",Adulteration concerns: US FDA warning letter to Sun Pharma questions manufacturing practices at Halol facility  ,"The US Food and Drug Administration (FDA) has slammed Sun Pharma, the country’s largest generic drug maker, for manufacturing violations such as failure to investigate discrepancies in batches of products, not cleaning equipment used in drug manufacturing and failing to prevent contamination at its Halol facility in Gujarat.In a warning letter, the FDA has highlighted a series of lapses at Sun Pharma’s Gujarat plant, which has been put on an import alert list by the US drug regulator.In the letter dated December 15, the FDA told Dilip Shanghvi, Managing Director, Sun Pharma, that it had observed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the Halol facility. “Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated,” the warning letter said.Also read | FDA's warning letter points to cGMP violations at Halol facility: Sun PharmaThe FDA inspected Sun Pharma’s Halol plant from April 26 to May 9, 2022.The company gave a detailed response to the US regulator on May 31 in response to Form 483. However, the FDA was not convinced and placed the Halol facility on import alert on December 7. In its letter, the US FDA pointed out that Sun Pharma failed to thoroughly investigate discrepancies in batches of products at the Halol facility.‘Putting patients at risk’The regulator said that in November 2021, despite experiencing significant media fill failure, resulting in serious flaws and risks, Sun Pharma failed to perform a timely risk assessment to evaluate if the quality and sterility of its distributed drug products were affected by these deficiencies.“You waited over five months to initiate a recall of the affected batches. The failure to proactively identify deficiencies and implement timely and sustainable corrective actions and preventive actions (CAPA) is unacceptable because it puts patients at risk,” the warning letter said.Also read | Sun Pharma clarifies on US FDA import alert on Halol plantThe FDA has further pointed out that Sun Pharma did not follow appropriate procedures to prevent contamination at the Halol facility. “Operators’ bodies and hands were in immediate proximity to the sterile active pharmaceutical ingredient (API) during dispensing, compounding, and syringe-loading in the filling station,” the letter said.The warning letter also said that the Hyderabad-based Pharma giant had failed to establish an adequate system to monitor environmental conditions. “Vigilant and responsive environmental and personnel monitoring programs should be designed to provide meaningful information on the state of control of your aseptic processing environment,” it said.According to the warning letter, Sun Pharma had acknowledged the inadequacies of the environmental and personnel monitoring programme, stating that the drug products impacted by the observation are being recalled, and that the specific filling line involved in the observation was no longer in use. “You fail to adequately explain how your quality and operations management will ensure appropriate cleanroom design, control, aseptic practices, and cleanroom behaviour during production,” the letter said.Failure to investigate discrepanciesThe US FDA’s warning letter said that Sun Pharma had failed to use suitable equipment in manufacturing drug products.“It is your responsibility to ensure that only appropriately designed and maintained equipment are used in the manufacture of your drug products,” the drug regulator said. It further stated: “Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed.”Sun Pharma has been asked to provide a comprehensive, independent assessment of its overall system for investigation of discrepancies and to provide an action plan detailing how it will fix this system.Drug contamination concernsThe warning letter from the US FDA also points out that Sun Pharma failed to sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the purity of a drug. The company has been asked to provide a comprehensive, independent retrospective assessment of cleaning effectiveness to evaluate the scope of cross-contamination hazards.Also read | FDA's warning letter points to cGMP violations at Halol facility: Sun PharmaSun Pharma has been told that basis the findings at the Halol facility, the firm does not have an effective quality system in accordance with CGMP.Company told to take corrective action immediatelyThe company has been asked to immediately carry out a comprehensive assessment of its global manufacturing operations to ensure that its systems, processes, and manufactured products conform to FDA requirements.“Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified to assist your firm in meeting CGMP requirements,” the FDA said.The regulator, however, says that engaging a consultant does not relieve the firm of its obligation to comply with CGMP. “Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance,” the FDA said.",Sun Pharmaceutical Industries Ltd.
"  January 11, 2023 / 03:23 PM IST  ",A portfolio of 19 stocks to stick with for a rewarding 2023,"                        The year 2022 was difficult for the Indian stock market. Nevertheless, amid volatility and uncertainty, the market did throw up several winners. While the outlook for 2023 is clouded, with forecasts ranging from extreme optimism to pessimism, we believe a well-researched portfolio can still produce gainers. Here’s a 19-stock portfolio that can help navigate an uncertain year. Wishing all our readers a very Happy New Year and a rewarding year of investing with MC Pro.

The following are the 19...
                    ",Syngene International Ltd.
"  January 11, 2023 / 06:31 AM IST  ","Trade Spotlight | What should you do with Tata Motors, Samvardhana Motherson, Zydus Lifesciences on Wednesday?","The market has largely been volatile and trading within the range of 17,750-18,300 on the Nifty50 for over a couple of weeks. On January 10, the benchmark indices wiped out more than half of previous day's gains and closed with 1 percent loss led largely by banking and financial services, technology and metal stocks.The BSE Sensex fell more than 600 points to 60,115, while the Nifty50 shed 187 points to 17,914 and formed long bearish candle which, to some extent, resembles Bearish Engulfing kind of pattern formation on the daily charts, indicating bears ruling over Dalal Street.The broader markets also traded in line with benchmarks with the Nifty Midcap 100 and Smallcap 100 indices declining half a percent and six-tenth of a percent respectively on weak breadth.Volatility increased sharply on Tuesday, giving discomfort for bulls. India VIX jumped 5.85 percent from 14.65 level, to 15.51 level.Stocks that bucked the trend on Tuesday included Tata Motors, which was the biggest outperformer among Nifty50 stocks, climbing 6 percent to Rs 412.90, the highest closing level since December 19, 2022 and formed long bullish candle on the daily charts with significantly higher volumes and making higher high higher low formation for second straight session.The stock had a strong gap-up opening and gave a healthy and decisive breakout of downward sloping resistance trendline adjoining December 1 and December 16, 2022, and also there was a breakout of long horizontal resistance trendline adjoining multiple touch points - May 11, June 22 and December 27, indicating the positive mood.Samvardhana Motherson International shares gained more than 2 percent at Rs 78.75, continuing uptrend for second consecutive session and formed bullish candle on the daily charts with above average volumes. In fact, it has extended rally on Tuesday after giving a breakout of downward sloping resistance trend line adjoining multiple touch points July 21, September 16, 2022, January 3, and January 4, 2023, as well as long horizontal resistance trend line adjoining multiple touch points - September 27, October 10, October 11, December 5, 2022, and January 3, 2023.Zydus Lifesciences was also in action, climbing 3 percent to Rs 457, the highest closing level since January 5, 2022 and formed strong bullish candle on the daily charts with healthy volumes, making higher high higher low for sixth consecutive session. The stock on January 5 this year, has seen a breakout of long downward sloping resistance trend line adjoining June 11, 2021 and November 10, 2022. Also there was a breakout of horizontal resistance trend line adjoining November 11, 2022 and January 9, 2023.Here's what Vaishali Parekh of Prabhudas Lilladher recommends investors should do with these stocks when the market resumes trading today:Tata MotorsThe stock has maintained a strong support zone near Rs 375-380 levels and has recently given a decent pullback to improve the bias moving past the significant 50-day EMA (exponential moving average) level of Rs 408 to strengthen the trend. The bias has turned positive with a strong bullish positive candle indication and is expected to rise further with initial targets of Rs 435-440 levels.The RSI (relative strength index) has turned up from the highly oversold zone and indicated a trend reversal to signal a buy. Further ahead a decisive move past the important 200DMA (daily moving average) level of Rs 427, would further trigger for fresh upward move and can anticipate for Rs 480-490 zone. The near term support would be near Rs 380 zone.Zydus LifesciencesThe stock after making a higher bottom formation pattern on the daily chart near Rs 390 level has gradually picked up and moving past the significant 50EMA level of Rs 408 has improved the bias and witnessed a decent rally with currently indicating a breakout above the trendline resistance of Rs 450 level to anticipate for further upside move.The chart looks attractive with a strong trend maintained with next target expected at Rs 490-500 levels. The near term support would be Rs 435 zone.Samvardhana Motherson International The stock after a short consolidation phase near Rs 75-76 zone has given a breakout to move ahead and indicating strength has scope for further upward move in the coming days.A decisive move above the significant 200DMA level of Rs 79.60 would further strengthen the trend and can trigger for fresh further upward move with targets anticipated at around Rs 86-89 levels. The near term support zone would be Rs 75, below which the trend can turn little bit weak.",Zydus Lifesciences Ltd.
